---

---

results   tags : Clinical-trials-phase-iii   

save search

---

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 0.75% | O: 0.75% H: 0.0% C: 0.0%
rinvoq positive cell results study

---

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M |

Health Technology

| -81.25% | O: -75.4% H: 5.41% C: -29.73%
first update pharmaceuticals trial financial results

---

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M |

Health Technology

| -4.84% | O: -1.01% H: 2.04% C: 1.17%
ajovy for teva trial migraine china results

---

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M |

Health Technology

| -6.29% | O: 1.29% H: 0.0% C: -3.93%
covid-19 vaccine positive trial results

---

Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
SEEL | $0.3502 3.61% 3.48% 290K |

Health Technology

| -64.04% | O: -54.24% H: 71.43% C: 54.76%
sls-005 update sclerosis therapeutics results study

---

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | News | $1.675 2.13% 2.09% 980K |

Health Technology

| -11.83% | O: 12.9% H: 5.71% C: -2.86%
corporation positive blood system topline trial cardiovascular results

---

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.78 19.97% 560 |

n/a

| 4.32% | O: -0.56% H: 0.0% C: -0.38%
AKLI | $0.239 2.93% 2.85% 50K |

| -50.3% | O: -3.85% H: 12.67% C: 6.92%
japan positive endeavorrx adhd trial results

---

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
AKLI | $0.239 2.93% 2.85% 50K |

| 1.44% | O: 193.1% H: 13.69% C: -30.36%
endeavorrx japan positive adhd trial results

---

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M |

Health Technology

| -7.0% | O: 0.07% H: 1.4% C: 0.92%
positive treatment fibrosis trials results

---

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K |

Health Technology

| -24.19% | O: -0.29% H: 2.11% C: 1.3%
covid-19 vaccine mrna therapeutics results

---

New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M |

Health Technology

| -50.0% | O: 2.78% H: 6.05% C: 4.59%
fda fibromyalgia approval hope trial results

---

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M |

Health Technology

| -9.38% | O: -1.34% H: 4.28% C: 3.74%
vx-548 positive treatment program results

---

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Published: 2024-01-18 (Crawled : 21:00) - biospace.com/
DCPH | $14.69 3.23% 3.13% 390K |

Health Technology

| 4.95% | O: 0.0% H: 1.77% C: -1.77%
symposium pharmaceuticals gastrointestinal results study

---

Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -2.62% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.4% | O: 1.04% H: 0.17% C: 0.11%
dupixent positive copd results sanofi

---

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
Published: 2023-11-01 (Crawled : 22:00) - biospace.com/
INVA | $14.955 1.8% 1.77% 640K |

Health Technology

| 16.68% | O: -0.56% H: 1.09% C: 0.65%
positive treat trial results

---

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Published: 2023-10-30 (Crawled : 12:00) - biospace.com/
RVPH | $3.035 0.5% 0.49% 140K |

| -19.47% | O: 33.6% H: 35.73% C: 9.58%
brilaroxazine positive global topline schizophrenia trial results

---

New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement
Published: 2023-10-23 (Crawled : 12:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -4.84% | O: 0.28% H: 0.0% C: 0.0%
tremfya response results show

---

Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT®
Published: 2023-09-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -9.72% | O: -0.37% H: 0.0% C: 0.0%
rybrevant study

---

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
Published: 2023-08-24 (Crawled : 22:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M |

Health Technology

| 31.05% | O: 0.49% H: 0.36% C: -1.95%
ipx203 disease parkinson’s results study

---

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
Published: 2023-08-24 (Crawled : 14:00) - biospace.com/
EXEL | $22.51 0.09% 0.09% 2.3M |

Health Technology

| 5.86% | O: 1.15% H: 0.66% C: -1.14%
tumors positive pancreatic trial results

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---